Moderna prepares to submit RSV vaccine for FDA approval

0
22

BREAKTHROUGH FOR US TO HAVE A VACCINE. >> MODERNA HAS PUBLISHED PRELIMINARY RESULTS OF THEIR RSV VACCINE SHOWING IT IS MORE THAN 80% EFFECTIVE IN PREVENTING SERIOUS DISEASE IN PEOPLE OVER 60 AND PREPARING FOR FDA APPROVAL. THIS FOLLOWS PFIZER AND GLAXOSMITHKLINE’S MATURALIZATION AT THE END OF LAST YEAR. >> THE PFIZER VACCINE, THEY ALSO PUBLISHED THE RESULTS OF GIVING THE SAME VACCINE TO PREGNANT WOMEN. AND THEN IT HAPPENS IN THE WOMAN: THE ANTIBODIES PRODUCED BY THE WOMAN PASS THROUGH THE PLACENTA TO THE CHILD. IN THE FIRST THREE MONTHS OF LIFE THEY PROVIDED VERY GOOD PROTECTION. >> YOUNG CHILDREN ARE ONE OF THE HIGH RISK GROUPS FOR DEVELOPING COMPLICATIONS AND DEATH FROM RSV. CLINICAL TRIALS OF THE VACCINE FOR THEM ARE IN PROGRESS. THESE WERE THE FIRST APPROVED VACCINES AGAINST RSV, A FEAT BECAUSE RESEARCHERS HAVE BEEN WORKING ON THEM SINCE THE 1960s. THE MODERNA VERSION USES THE MRNA TECHNOLOGY WHICH HAS BECOME KNOWN FOR THE PRODUCTION OF COVID. >> THE REASON THEY COULD MOVE SO QUICKLY TO THE COVID VACCINE WAS BECAUSE THEY ALREADY STUDIED THIS VACCINE, THIS RSV VACCINE THAT WE’RE LEARNING ABOUT NOW, AND THEY USED THE SAME TECHNOLOGY AND A LOT OF THEIR TRICKS THAT THEY KNOW THIS IS TO DEVELOP A VACCINE AGAINST COVID. Dr. Campbell cautions that these results are preliminary and do not constitute peer review. SO PROMISING HE IS AWAITING FULL DETAILS. >> DOESN’T DETRACT THAT THIS IS REALLY EXCITING NEWS. BUT I AND I THINK EVERYONE SHOULD WAIT FOR THE FINAL, ALL THE DATA SHOWS. FOR THIS AND OTHER RSV VACCINES. >> DR. CAMPBELL SAYS RESEARCHERS HOPE SOME OF THESE VACCINES WILL BE READY BY THIS YEAR’S RSV. SEASON THIS FALL.

Researchers on the brink of a new RSV vaccine

Study: Moderna RSV vaccine more than 80% effective at preventing RSV in older adults

Researchers are on the verge of releasing a new vaccine to fight the respiratory syncytial virus amid an increase in cases in recent months. RSV has become the second leading cause of hospitalization, and tens of thousands of people die from it each year. Children under the age of 2 and adults over the age of 60 are most at risk of serious illness, and a vaccine has been elusive – until now. “It would be a huge breakthrough for us to have an RSV vaccine,” said Dr. James. Campbell, professor of pediatrics and the University of Maryland School of Medicine. RELATED: Sinai pediatrician describes intensive care unit presence amid rising RSV cases Moderna has released preliminary results of its RSV vaccine that show it is more than 80% effective at preventing serious illness in people over 60. The company is preparing to file a vaccine to the Food and Drug Administration for approval, which followed applications from Pfizer and GlaxoSmithKline late last year. “The Pfizer vaccine, they also reported the results of administering that same vaccine to pregnant women, and then what happens is the antibodies that the woman makes cross the placenta to the baby, and they showed very good protection in the first three months of life,” Campbell said. . vaccine trials are underway for infants and young children who are at high risk of complications and death from RSV. RELATED: Maryland hospitals concerned about surge in children with RSV. These would be the first approved RSV vaccines, which would be a feat because researchers have been working on them since the 1960s. Moderna’s version uses the mRNA technology made famous by the COVID-19 vaccine. The reason they were able to move so quickly to the COVID vaccine was because they were already studying this RSV vaccine that we’re just now learning about, and they used the same technology and a lot of tricks that they found out of it , to develop a vaccine against COVID,” Campbell said. Below is a playlist of the RSV video: Campbell cautioned that the results of the RSV vaccine study are preliminary and have not yet been peer-reviewed, so while promising, he is waiting for full information.” That doesn’t take away from the fact that this is really exciting news, but I think everyone should wait to see what the final data is on this vaccine and other RSV vaccines,” Campbell said. Campbell said researchers hope that some of these vaccines will be approved in time for RSV season in the fall LINK: Maryland Department of Health RSV website

Researchers are on the verge of releasing a new vaccine to fight the respiratory syncytial virus amid an increase in cases in recent months.

RSV has become the second leading cause of hospitalization, and tens of thousands of people die from it each year. Children under the age of 2 and adults over the age of 60 are at greatest risk of serious illness, and until now the vaccine has been elusive.

“It would be a huge breakthrough for us to have a vaccine against RSV,” said Dr. James Campbell, a professor of pediatrics and the University of Maryland School of Medicine.

RELATED: Sinai Pediatrician Describes ICU Availability Amid Rising RSV Cases

Moderna released preliminary results of its RSV vaccine it shows that it is more than 80% effective in preventing serious diseases in people over 60 years of age. The company is preparing to submit the vaccine for approval to the Food and Drug Administration after Pfizer and GlaxoSmithKline stepped in late last year.

“The Pfizer vaccine, they also reported the results of administering that same vaccine to pregnant women, and then what happens is that the antibodies that the woman makes cross the placenta to the baby, and they showed very good protection in the first three months of life,” Campbell said.

Clinical trials of the vaccine are underway for infants and young children who are at high risk of complications and death from RSV.

RELATED: Maryland hospitals are concerned about the rising number of children with RSV

These would be the first approved RSV vaccines, which would be a feat because researchers had been working on them since the 1960s. The Moderna version uses The mRNA technology became famous thanks to the vaccine against COVID-19.

“The reason they were able to move so quickly to the COVID vaccine was because they were already studying this RSV vaccine that we’re just now learning about, and they used the same technology and a lot of the tricks that they found with of this, to develop a vaccine against COVID,” Campbell said.

The RSV video playlist is below:

Campbell cautioned that the results of the RSV vaccine study are preliminary and have not yet been peer-reviewed, so while promising, he is waiting for full details.

“That doesn’t take away from the fact that this is really exciting news, but I think everyone should wait to see what the final, full data show for this vaccine and other RSV vaccines,” Campbell said.

Campbell said researchers hope to have some of these vaccines approved in time for RSV season in the fall.

LINK: Maryland Department of Public Health website for RSV

Moderna prepares to submit RSV vaccine for FDA approval

Source link Moderna prepares to submit RSV vaccine for FDA approval